Post hoc comparative analysis with historical data
ADVERSE EVENTS
We performed post hoc analyses and compared the OS and RFS data from our study with historical data for patients who received standard-of-care (nCRT or nCT) in our previously published CMISG1701 study. The favorable safety profile in the NATION-1907 trial was in stark contrast to standard therapeutic strategies observed in our CMISG1701 trial, in which nCRT and nCT were associated with 15.3% and 6.9% grade 3 or more treatment-related adverse events, respectively (Extended Data Fig. 